SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential.
Eur Rev Med Pharmacol Sci
; 24(14): 7880-7885, 2020 07.
Article
in English
| MEDLINE | ID: covidwho-693519
ABSTRACT
The coronavirus SARS-CoV-2 at the origin of COVID-19 shares more than 70% genetic similarity with SARS-CoV-1 that was at the origin of 2003 SARS. Infection-associated symptoms are very similar between SARS and COVID-19 diseases and are the same as community-acquired pneumonia symptoms. Antibiotics were empirically given to SARS patients in the early stages of the pathology whereas a different strategy has been decided in the management of COVID-19 pandemic with a worldwide shutdown. The cytokine storm, both identified in SARS and COVID-19 severe cases, is generated through inflammasome activation, which opens therapeutic perspectives to counteract the pathogenic inflammation. As corticoids have numerous side effects that limit their use, focusing on anti-inflammasome agents could represent a safer alternative for patients with severe COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Severe Acute Respiratory Syndrome
/
Anti-Bacterial Agents
Type of study:
Observational study
Limits:
Humans
Language:
English
Journal:
Eur Rev Med Pharmacol Sci
Journal subject:
Pharmacology
/
Toxicology
Year:
2020
Document Type:
Article
Affiliation country:
Eurrev_202007_22293
Similar
MEDLINE
...
LILACS
LIS